Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1001 - Efficacy and safety for apatinib combined with oxaliplatin and S1 in initially treated metastatic gastric cancer ----- a single-center observational study

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Gastric Cancer

Presenters

Jianjun Peng

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

J. Peng, L. Peng, H. Wu, K. Wu, W. Chen, C. Xie, J. Xu, X. Zhang, D. Chen, S. Cai, Y. He

Author affiliations

  • Gastrointestinal Surgery Center, the First Affiliated Hospital of Sun Yat-sen University, 510080 - Guangzhou/CN
More

Resources

Abstract 1001

Background

Currently, S-1 combined with oxaliplatin (SOX) is widely used in the first-line treatment of advanced gastric cancer in China. Apatinib has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models. We evaluated the efficacy and safety of apatinib combined with SOX in initially treated patients with metastatic gastric cancer.

Methods

In this single arm study, patients with unresectable metastatic gastric adenocarcinoma was enrolled to received chemotherapy with apatinib (500mg, once daily) and SOX regimen. Oxaliplatin was administered at a dose of 130 mg/m2 on day 1, and S-1 (40–60 mg depending on patient’s body surface area) was given orally twice daily for 2 consecutive weeks followed by a 1-week rest. The primary end point was response rates, Secondary endpoints were safety, median progression-free survival and median overall survival.

Results

Thirty-one eligible patients were enrolled between January 2016 and September 2017. Two patients achieved a complete response and 19 patients had partial response. The objective response rates was 67.7%. Seven patients had stable disease and the disease control rates was 90.3%. Disease progression was seen in 3 cases (9.7%). Progression-free survival was 5.9 months (95% confidence interval: 3.2–12.6) and median overall survival was 13.6 months (95% confidence interval: 7.3–22.1). The most common grade 3 to 4 hematologic adverse events (AE) were leucopenia (12.9%), neutropenia (38.7%), thrombocytopenia (6.5%) and anaemia (25.8%), nonhematologic AE were nausea (12.9%), anorexia (32.3%), hand-foot syndrome (6.5%), hypertension (9.7%) and proteinuria (3.2%). No treatment-related death was documented during the drug administration.

Conclusions

Apatinib plus SOX is effective for initially treated metastatic gastric cancer with more favorable safety.

Clinical trial identification

Legal entity responsible for the study

Peng Jianjun.

Funding

Has not received any funding.

Editorial Acknowledgement

Approved by the hospital ethics committee of the first affiliated hospital of Sun Yat-sen University (SYU).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.